Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475 versus platinum-based chemotherapy in first-line PD-L1-strong metastatic non-small cell lung cancer
NL-OMON44857Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2014
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing MK-3475 with Standard of care platinum-based chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Aug 2014; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44857.